Bazedoxifene (Conbriza®)

Assessment Status Rapid Review complete
Drug Bazedoxifene
Brand Conbriza®
Indication Treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.
Assessment Process
Rapid review commissioned 20/09/2011
Rapid review completed 02/11/2011
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.